Oncology Research and Treatment
Journal Abbreviation: Oncol Res Treat
ISSN: 2296-5270
eISSN: 2296-5262
Publisher: Karger Publishers
Publications (241)
Stromal cells enhance PD-L1 expression on CLL cells via the oncogenic Notch-cMyc-EZH2 signaling axis (2020)
Böttcher M, Mentz K, Popp S, Saul D, Bruns H, Mackensen A, Mougiakakos D, Völkl S
Conference contribution
N-glycosylation controls inflammatory licensing-triggered PD-L1 upregulation in human mesenchymal stromal cells (2020)
Strauch V, Saul D, Mackensen A, Jitschin R, Mougiakakos D
Conference contribution
Immunometabolic alterations in lymphoma patients with early relapse upon autologous stem cell transplantation (2020)
Richter S, Jacobs B, Mackensen A, Mougiakakos D, Völkl S
Conference contribution
Low-dose interleukin-2 for the treatment of glucocorticoid-refractory acute graft-versus-host disease: a single center experience (2020)
Brandt A, Vasova I, Winkler J, Mackensen A, Rösler W, Spoerl S, Völkl S
Conference contribution
Profiling extracellular vesicles (EV) in patients with acute GvHD after allogeneic stem cell transplantation (2020)
Böttcher M, Stoll A, Böttcher-Loschinski R, Rösler W, Winkler J, Mackensen A, Mougiakakos D, et al.
Conference contribution
Fever of unknown origin following allogeneic stem cell transplantation - an unusual case (2020)
Meintker L, Kremer A, Brandt A, Spoerl S, Slanikova A, Mackensen A, Winkler J, Rösler W
Conference contribution
CD19 CAR-T cell treatment of CNS relapse of Burkitt's lymphoma: A case report (2020)
Aigner M, Jacobs B, Gary R, Kretschmann S, Achenbach S, Mackensen A, Mougiakakos D, et al.
Conference contribution
4-1BB/CD137 triggering on human monocytes leads to differentiation into macrophages with increased metabolic support and tumoricidal capacity (2020)
Stoll A, Bruns H, Gamali S, Saul D, Mackensen A, Mougiakakos D
Conference contribution
Impact of Nrf2 expression in reconstituting T-cells of allogeneic hematopoietic stem cell transplanted patients (2020)
Karl F, Stoll A, Gamali S, Böttcher-Loschinski R, Böttcher M, Baur R, Jacobs B, et al.
Conference contribution
A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast) (2020)
Ahrens M, Escudier B, Boleti E, Grimm MO, Goupir MG, Barthelemy P, Gravis G, et al.
Conference contribution